Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M342Revenue (TTM) $M26.3Net Margin (%)-113.9Altman Z-Score-0.7
Enterprise Value $M221EPS (TTM) $-0.6Operating Margin %-118.4Piotroski F-Score4
P/E(ttm)--Beneish M-Score3.3Pre-tax Margin (%)-113.9Higher ROA y-yY
Price/Book8.410-y EBITDA Growth Rate %--Quick Ratio2.8Cash flow > EarningsY
Price/Sales12.85-y EBITDA Growth Rate %38.5Current Ratio2.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-20.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-59.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M48.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CCXI

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

CCXI is held by these investors:

CCXI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LUCAS ROGER CDirector 2017-08-01Sell2,250$10.07-30.19view
Bekker PetrusChief Medical Officer 2017-07-13Sell76,013$9.95-29.35view
Bekker PetrusChief Medical Officer 2017-07-10Sell19,877$9.3-24.41view
Bekker PetrusChief Medical Officer 2017-06-30Sell65,509$9.17-23.34view
LUCAS ROGER CDirector 2017-05-01Sell4,000$7.31-3.83view
LUCAS ROGER CDirector 2017-02-01Sell4,000$7.32-3.96view
Cappel Markus J.Chief Bus. Officer & Treasurer 2017-01-03Sell26,821$7.51-6.39view
Bekker PetrusChief Medical Officer 2016-12-16Sell8,712$8.74-19.57view
Bekker PetrusChief Medical Officer 2016-12-05Sell30,000$8.5-17.29view
Bekker PetrusChief Medical Officer 2016-11-22Sell1,250$8.3-15.3view

Press Releases about CCXI :

Quarterly/Annual Reports about CCXI:

News about CCXI:

Articles On GuruFocus.com
ChemoCentryx to Present at Three Upcoming Investor Conferences Sep 05 2017 
ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, Jul 26 2017 
Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Poten Jun 06 2017 
ChemoCentryx to Present at Two Upcoming Investor Conferences May 24 2017 
ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney May 23 2017 
ChemoCentryx Reports First Quarter 2017 Financial Results May 10 2017 
ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017 Apr 27 2017 
ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidn Mar 22 2017 
ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results Mar 14 2017 
ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 201 Mar 01 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat